The Summary
This review examines emerging evidence on tirzepatide, a dual GIP/GLP-1 receptor agonist, for treating obstructive sleep apnea (OSA) in individuals with obesity. Researchers found that tirzepatide significantly reduces the apnea-hypopnea index, which measures breathing interruptions. Consequently, it recently became the first FDA-approved medication specifically for moderate-to-severe OSA in adults with obesity. Beyond alleviating breathing issues and promoting weight loss, the drug is associated with decreased cardiovascular, liver, and kidney complications, making it a powerful systemic therapy.
Why this is interesting
Standard sleep apnea treatment usually requires wearing a cumbersome CPAP machine every night. While effective, many patients struggle to use it consistently. This review highlights a game-changing alternative: tirzepatide, a popular weight-loss injection, targets the underlying cause by reducing excess weight that narrows the airway. For millions of adults with obesity and sleep apnea, this means a single medication could help shed pounds, reduce dangerous breathing interruptions, and protect heart health, potentially offering an alternative to traditional therapies.